KR20230053602A - 항-ror1 항체 및 관련된 이중특이적 결합 단백질 - Google Patents

항-ror1 항체 및 관련된 이중특이적 결합 단백질 Download PDF

Info

Publication number
KR20230053602A
KR20230053602A KR1020237005603A KR20237005603A KR20230053602A KR 20230053602 A KR20230053602 A KR 20230053602A KR 1020237005603 A KR1020237005603 A KR 1020237005603A KR 20237005603 A KR20237005603 A KR 20237005603A KR 20230053602 A KR20230053602 A KR 20230053602A
Authority
KR
South Korea
Prior art keywords
ser
ror1
antibody
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005603A
Other languages
English (en)
Korean (ko)
Inventor
시용 공
케동 오우양
쳉빈 우
단칭 우
쑤언 우
루이 장
Original Assignee
에피맙 바이오테라퓨틱스 (에이치케이) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에피맙 바이오테라퓨틱스 (에이치케이) 리미티드 filed Critical 에피맙 바이오테라퓨틱스 (에이치케이) 리미티드
Publication of KR20230053602A publication Critical patent/KR20230053602A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237005603A 2020-08-24 2021-08-23 항-ror1 항체 및 관련된 이중특이적 결합 단백질 Pending KR20230053602A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/110841 2020-08-24
CN2020110841 2020-08-24
CNPCT/CN2020/141398 2020-12-30
CN2020141398 2020-12-30
PCT/CN2021/114088 WO2022042488A1 (en) 2020-08-24 2021-08-23 Anti-ror1 antibodies and related bispecific binding proteins

Publications (1)

Publication Number Publication Date
KR20230053602A true KR20230053602A (ko) 2023-04-21

Family

ID=77946069

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005603A Pending KR20230053602A (ko) 2020-08-24 2021-08-23 항-ror1 항체 및 관련된 이중특이적 결합 단백질

Country Status (12)

Country Link
US (1) US20240010753A1 (cg-RX-API-DMAC7.html)
EP (1) EP4200336A4 (cg-RX-API-DMAC7.html)
JP (1) JP7781859B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230053602A (cg-RX-API-DMAC7.html)
CN (2) CN114085288A (cg-RX-API-DMAC7.html)
AU (1) AU2021334677A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002895A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190117A1 (cg-RX-API-DMAC7.html)
IL (1) IL300760A (cg-RX-API-DMAC7.html)
MX (1) MX2023002181A (cg-RX-API-DMAC7.html)
TW (1) TWI907489B (cg-RX-API-DMAC7.html)
WO (1) WO2022042488A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN114539411B (zh) * 2022-04-29 2022-11-11 山东博安生物技术股份有限公司 一种ror1抗体或其抗原结合片段
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
CN118974090A (zh) * 2022-04-02 2024-11-15 山东先声生物制药有限公司 抗ror1的抗体及其用途
CA3262028A1 (en) * 2022-07-15 2025-06-13 Abl Bio Inc. Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses
CN116836286A (zh) * 2022-09-07 2023-10-03 中国科学院合肥物质科学研究院 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024094151A1 (en) * 2022-11-03 2024-05-10 Hansoh Bio Llc Multi-specific antibody and medical use thereof
AU2024331841A1 (en) * 2023-08-31 2026-03-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof
WO2025061032A1 (zh) * 2023-09-18 2025-03-27 南京蓬勃生物科技有限公司 靶向人源ror1和cd3的双特异性抗体
TW202542204A (zh) * 2023-12-29 2025-11-01 大陸商上海岸邁生物科技有限公司 融合蛋白及其用途
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
CN122376773A (zh) * 2025-01-14 2026-07-14 正大天晴药业集团股份有限公司 靶向受体酪氨酸激酶样孤儿受体1的抗体药物偶联物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242014B2 (en) * 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
EP3252076B1 (en) * 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
JP2017536341A (ja) * 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのCD3εおよびROR1に対する二特異性抗体
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
HK1253507A1 (zh) * 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
HK1251480A1 (zh) * 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CA3001941A1 (en) * 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
CA3011419A1 (en) * 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AR108034A1 (es) * 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
KR102999339B1 (ko) * 2018-04-18 2026-07-31 엑셀리시스, 인코포레이티드 항-ror 항체 구조체
EA202192103A1 (ru) * 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
CN111286512A (zh) * 2019-06-05 2020-06-16 南京艾德免疫治疗研究院有限公司 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途
KR20220035369A (ko) * 2019-06-07 2022-03-22 아디맵 엘엘씨 고 친화도 항-cd3 항체, 및 이의 생성 및 사용 방법
TWI774137B (zh) * 2019-11-26 2022-08-11 大陸商上海岸邁生物科技有限公司 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白

Also Published As

Publication number Publication date
EP4200336A4 (en) 2024-09-25
CA3190117A1 (en) 2022-03-03
CN114085288A (zh) 2022-02-25
US20240010753A1 (en) 2024-01-11
BR112023002895A2 (pt) 2023-03-21
JP2023538945A (ja) 2023-09-12
IL300760A (en) 2023-04-01
JP7781859B2 (ja) 2025-12-08
TW202227491A (zh) 2022-07-16
AU2021334677A1 (en) 2023-03-02
WO2022042488A1 (en) 2022-03-03
CN113480656A (zh) 2021-10-08
MX2023002181A (es) 2023-03-02
CN113480656B (zh) 2022-06-03
TWI907489B (zh) 2025-12-11
EP4200336A1 (en) 2023-06-28

Similar Documents

Publication Publication Date Title
JP7781859B2 (ja) 抗ror1抗体及び関連の二重特異性結合タンパク質
JP7847630B2 (ja) Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質
US20250002594A1 (en) Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
TW202041537A (zh) 針對lag-3之工程化抗體及自其製備之雙特異性pd-1/lag-3結合蛋白
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
US20250282881A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
HK40061499A (en) Anti-ror1 antibodies
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
BR122025002178A2 (pt) Anticorpos para cd3 e bcma, e proteínas de ligação biespecíficas feitas a partir dos mesmos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240823

Comment text: Request for Examination of Application